Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q2 FY23 Earnings Presentation
35 slides from Krishna Institute Of Medical Sciences's earnings presentation, Nov 11, 2022
Slide 1: KIMS Hospitals - Investor presentation cover letter
KIMS HOSPITALS'" 11'h Novcmbcr, 2022 The General Manager, Thc Managcr, Depanrnent of Corpotate services Listing Depanment Bombav Stock Exchange Ltd (BSE) National Stock Exchange oflndia Limited, Phnozr Ihccihcclnror l'orvcrs, lixchange I,hza, 5rh Floor, DalalStreet, Phr No.(i/ l, '(i'Bl<,ck, N{umbai
Slide 2: Making Quality Healthcare Accessible & Affordable
MAKING QUALITY HEALTHCARE ACCESSIBLE & AFFORDABLE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Paradise Circle (290) Nagpur (334) Kondapur (200) Nashik (Under Construction) Gachibowli (237) Karimnagar (75) Andhra Pradesh Visakhapatnam (434) Srikakulam (200) Rajahmundry (195) • BEDS (4,000+) Ongole (350) • DOCTORS (1,607) Kurnool (200)
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. Well known i
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 8: Board of Directors
Board of Directors Mr. Rajeswara Rao G Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Shantanu Rastogi Independent Director, Managing Director Chief Executive Officer Whole-time Director Non-Executive Director Chairman (Stakeholders’ Relationship Committee) Mr. Saumen Chakrab
Slide 9: Shareholding Pattern - September 2022
Shareholding Pattern - 30 September, 2022 th Retail Pre IPO, Retail, 3.1% 8.9% Clearing Share Holder No of Shares Share Holding % Category Members, Promoter & Promoter Promoter 31,086,304 38.84% 0.1% Group, 38.8% General Atlantic 8,339,147 10.42% ICICI Ventures 1,939,393 2.42% Mirae Asset MF 7,345,2
Slide 10: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci O-Arm Scanner Spy Glass Fibroscan Robotic Surgical Multi-dimensional surgical State of the art add on to Specialized non-invasive System imaging platform optimized ERCP that allows doctors to diagnostic ultrasound-based Facilitates complex for use in spine
Slide 11: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 12: Key Accomplishments
Key Accomplishments Pharmacie De Qualite (PDQ) ‘Best Patient Friendly Hospital’ ‘Best Hospital to Work For’ Certification Overall PDQ Evaluation Ranked No. 1 Hospital AHPI Health Care Excellence AHPI Global Conclave Performance Score - 98% by Times of India, Hyderabad Award (2017) Award (2019) Gradi
Slide 13: Consistent performer over 2 decades
Consistent performer over 2 decades (Rupees in Millions) 5,217 16,711 7% 11,287 7% 7. 10,741** 2. 2,759** R:2 R :3 G C A CAG 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 H1-2023 2005 2010 2015 2020 2022 H1-2023 No. of No. of No. of No. of No. of No. of Hospitals: 1 Hospitals: 1 Hospital
Slide 14: Q2 Updates
Q2 Updates 13 Private & Confidential
Slide 15: Stellar performance across parameters
Stellar performance across parameters HIGHEST EVER HIGHEST EVER HIGHEST EVER HIGHEST EVER REVENUE* EBITDA** DISCHARGES OP FOOTFALL FOR A QUARTER FOR A QUARTER FOR A QUARTER FOR A QUARTER INR 5,733 Mn INR 1,447 Mn 46,000+ 375,000+ *Revenue represents total revenue **EBITDA before IND AS 116 and other
Slide 16: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 FINANCIAL HIGHLIGHTS Q2 FY 23 Consolidated • From 1st September’22, M/s SPANV Medisearch Lifesciences Private Limited (Kingsway Hospital, Nagpur) has become a subsidiary of “KIMS Hospitals”, post-acquisition of a 51% stake. It will be first operating hospital
Slide 17: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 FINANCIAL HIGHLIGHTS • Consolidated Revenue from operation grew by 13.8% QoQ basis to Rs. 5,641 mn, Ex Nagpur grew by 11%. • Consolidated Adjusted EBITDA (Excluding Other Income, INDAS adjustments and old case of Luxury Tax payment) grew by 14.5% on QoQ basis
Slide 18: Digital & ESG Initiatives
Digital & ESG Initiatives DIGITAL INITIATIVES During the quarter, steady progress was made on digital transformation with notable initiatives as below: • Docs App 2.0 (An integrated app for doctors to manage patient progress) was rolled out across all units (except Nagpur and Sunshine). • With the l
Slide 19: Group Operating Performance - 1/3
Group Operating Performance - 1/3 IP VOLUME (‘000) OP VOLUME (‘000) 15.5% 137 17.5% 47 1014 375 117 40 830 325 36 700 280 86 FY21 FY22 H1 FY23 Q2 FY22 Q1 FY23 Q2 FY23 FY21 FY22 H1 FY23 Q2 FY22 Q1 FY23 Q2 FY23 OCCUPANCY* ARPOB (‘000) (3.2%) 78.6% 79.9% 81.6% 29.6 30.2 29.2 7.2% 69.2% 72.6% 25.3 24.9
Slide 20: Group Operating Performance - 2/3
Group Operating Performance - 2/3 (Rupees in Millions) TOTAL REVENUE EBITDA* 14.5% 10.3% 16,711 5,733 5,217 1,447 5,008 1,279 1,312 13,401 4,171 3,672 10,741 2,759 FY21 FY22 H1 FY23 Q2 FY22 Q1 FY23 Q2 FY23 FY21 FY22 H1 FY23 Q2 FY22 Q1 FY23 Q2 FY23 PBT 14.2% PAT 15.1% 4,569 1,226** 3,438 912** 1,132
Slide 21: Group Operating Performance - 3/3
Group Operating Performance - 3/3 (Rupees in Millions) Particulars FY21 FY22 Q1 FY23 Q2 FY23 H1 FY23 Bed Capacity 3,064 3,064 3,666 4,015 4,015 Operational Beds 2,590 2,590 3,222 3,543 3,543 Census Beds 2,246 2,246 2,760 3,026 3,026 Non Census Beds 344 344 462 517 517 Occupied Beds 1,765 1,793 1,807
Slide 22: Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2
Comparison of Telangana and Andhra Pradesh Matured Hospitals - 1/2 (Rupees in Millions) Telangana (KIMS) AP Matured Assets Particulars FY21 FY22 Q1 FY 23 Q2 FY23 H1 FY23 FY21 FY22 Q1 FY23 Q2 FY23 H1 FY23 Bed Capacity 1,200 1,200 1,200 1,200 1,200 630 630 630 645 645 Operational Beds 1,035 1,035 1,06
Slide 23: Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2
Comparison of Andhra Pradesh Acquired, Sunshine & Nagpur - 2/2 (Rupees in Millions) AP Acquired Assets Sunshine Nagpur Group Particulars FY21 FY22 Q1 FY23 Q2 FY23 H1 FY23 Q1 FY23 Q2 FY23 H1 FY23 Q1 FY23 FY21 FY22 Q1 FY23 Q2 FY23 H1 FY23 Bed Capacity 1234 1234 1234 1234 1234 602 602 602 334 3,064 3,0
Slide 24: Speciality Mix
Speciality Mix Others Cardiac Science 23% 19% Renal Sciences 9% Mother & Child 8% Group H1 FY 23 Organ Oncology Transplant 5% 2% Gastric Sciences 8% Neuro Sciences 12% Orthopaedics 14% Includes Sunshine and 1 month (Sept’22) of Nagpur 23 Private & Confidential
Slide 25: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra AP Mature 1.3% 10.9% Aarogyasri 7% AP Non Mature 15.7% Corporate Cash H1 FY23 12% 55% Telangana 72.1% H1 FY23 CLUSTER EBITDA* Maharashtra AP Mature Insurance 0.5% 13.7% 26% AP Non Mature 11.9% H1 FY23 *EBITDA before IND AS 116 and o
Slide 26: Key Achievements in Q2 FY23
Key Achievements in Q2 FY23 25 Private & Confidential
Slide 27: Key Achievements in Q2 FY23
Key Achievements in Q2 FY23 26 Private & Confidential
Slide 28: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 27 Private & Confidential
Slide 29: Disciplined growth strategy in adjacent markets
Kims has a disciplined growth strategy - strategically grow in adjacent markets some of which are ‘natural extensions’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Indore, Aurangabad, Nagpur & Raipur): KIMS flagship hospit
Slide 30: Update on Expansion Plans
Update on Expansion Plans 29 Private & Confidential
Slide 31: Future vision taking shape - Construction update
Future vision taking shape - Construction update KIMS-SUNSHINE KIMS HOSPITALS KIMS-MANAVATA KIMS-ICON GASTRO UNIT BEGUMPET BANGALORE NASHIK VISAKHAPATNAM 30 Private & Confidential
Slide 32: Expansion plans
Expansion plans Current Incremental New Approx. Approx. Timeline Units Beds Beds Departments Capex (Starting April 2021) Kondapur 200 500 All Specialities 300 Cr 36-42 months Vizag 434 50 Cancer Centre 15-20 Cr 36 months Cancer Centre / Anantapur 250 150 50-60 Cr 36-48 months Mother & Child Ongole 3
Slide 33: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Particulars Q2 FY 23 Q1 FY 23 Q2 FY 22 QoQ(%) YoY(%) FY 22 FY 21 YoY(%) Operating Revenue 5,641 4,955 4,117 13.8% 37.0% 16,508 13,299 24.1% Other Income 92 53 54 72.5% 70.2% 203 102 99.3% Total Revenue 5,733 5,008 4,171 14.5% 37.4% 16,711 13,401 24.7% E
Slide 34: Corporate Structure
Corporate Structure Krishna Institute of Medical Sciences Ltd. KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Sarvejana KIMS-Manavata SPANV KIMS Hospitals Srikakulam Kondapur Vizag Anantapur Kurnool (Sunshine) Nashik Nag
Slide 35: Thank You
Thank You 34 Private & Confidential
Krishna Institute of Medical Sciences — Q2 FY23 Earnings Presentation on 6ix